OraSure Technologies (NASDAQ:OSUR) develops and manufactures diagnostic products, specimen collection devices, and molecular testing solutions. The company’s offerings are designed for use by consumers, healthcare providers, laboratories, public health organizations, and research customers, with an emphasis on convenient and less-invasive sample collection and testing.
OraSure is best known for its OraQuick portfolio, which has included rapid tests for HIV and hepatitis C that use oral-fluid or finger-stick samples. The company has also developed products for infectious-disease testing, including rapid COVID-19 tests, as well as saliva- and other specimen-collection systems used in molecular diagnostics, genetic testing, and laboratory research.
Through its molecular solutions businesses, including DNA Genotek and related operations, OraSure provides collection and stabilization products that enable the transport and analysis of DNA, RNA, and other biological samples. Its products are marketed internationally through direct sales, distributors, commercial laboratories, and strategic partners, serving customers in North America and other global markets. OraSure is headquartered in Bethlehem, Pennsylvania.
